Patents by Inventor Tinya Abrams

Tinya Abrams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CKIT antibody drug conjugates
    Patent number: 11833215
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 5, 2023
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • PHARMACEUTICAL COMBINATION COMPRISING LSZ102 AND RIBOCICLIB
    Publication number: 20220031657
    Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Inventors: Tinya ABRAMS, Larry Alexander GAITHER
  • Pharmaceutical combination comprising LSZ102 and ribociclib
    Patent number: 11179365
    Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: November 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Tinya Abrams, Larry Alexander Gaither
  • PHARMACEUTICAL COMBINATION COMPRISING LSZ102 AND ALPELISIB
    Publication number: 20210000810
    Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.
    Type: Application
    Filed: May 7, 2020
    Publication date: January 7, 2021
    Inventors: Tinya Abrams, Larry Alexander Gaither
  • CKIT ANTIBODY DRUG CONJUGATES
    Publication number: 20200405875
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 31, 2020
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William Mallet, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • CKIT antibody drug conjugates
    Patent number: 10786578
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Pharmaceutical combination comprising LSZ102 and alpelisib
    Patent number: 10695333
    Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 30, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Larry Alexander Gaither
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20200129632
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 30, 2020
    Inventors: Tinya ABRAMS, Steven COHEN, Christie P. FANTON, Catrin FINNER, Thomas HUBER, Kathy MILLER, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • Antibody drug conjugates
    Patent number: 10626172
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 21, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20190194315
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: June 17, 2016
    Publication date: June 27, 2019
    Applicant: Novartis AG
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Joseph Anthony D'Alessio, Jason Damiano, Clemens Durr, Bernhard Hubert GEIERSTANGER, Qi-Ying HU, Thomas HUBER, Hidetomo IMASE, Yunho JIN, Daniel MENEZES, Kathy MILLER, Morvarid MOHSENI, Weijia OU, Katherine RENDAHL, Tetsuo UNO, Yongqin WAN, Xing WANG
  • PHARMACEUTICAL COMBINATION COMPRISING LSZ102 AND ALPELISIB
    Publication number: 20190167652
    Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.
    Type: Application
    Filed: November 29, 2018
    Publication date: June 6, 2019
    Inventors: Tinya ABRAMS, Larry Alexander GAITHER
  • PHARMACEUTICAL COMBINATION COMPRISING LSZ102 AND RIBOCICLIB
    Publication number: 20190142796
    Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.
    Type: Application
    Filed: November 14, 2018
    Publication date: May 16, 2019
    Inventors: Tinya ABRAMS, Larry Alexander GAITHER
  • Antibody Drug Conjugates
    Publication number: 20190119375
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: May 24, 2018
    Publication date: April 25, 2019
    Applicant: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
  • Antibody drug conjugates
    Patent number: 10117953
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 6, 2018
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
  • CKIT ANTIBODY DRUG CONJUGATES
    Publication number: 20180193475
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: July 27, 2015
    Publication date: July 12, 2018
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William MALLET, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • Antibody drug conjugates
    Patent number: 10005836
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20180125996
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: August 30, 2017
    Publication date: May 10, 2018
    Inventors: Tinya ABRAMS, Steven COHEN, Christie P. FANTON, Catrin FINNER, Thomas HUBER, Kathy MILLER, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • cKIT antibody drug conjugates
    Patent number: 9789203
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 17, 2017
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Cohen, Christie P. Fanton, Catrin Finner, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20170035905
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: October 3, 2016
    Publication date: February 9, 2017
    Applicant: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
  • Antibody drug conjugates
    Patent number: 9498543
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner